Literature DB >> 19528496

The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.

A Martschick1, J Sehouli, Alexa Patzelt, H Richter, U Jacobi, G Oskay-Ozcelik, W Sterry, J Lademann.   

Abstract

BACKGROUND: Anthracyclines, such as pegylated liposomal doxorubicin (PLD) and epirubicin (EP), are effective for the treatment of malignant tumors. Unfortunately, their implementation in therapy is limited due to severe side-effects such as palmar-plantar erythrodysesthesia (PPE). PATIENTS AND METHODS: As the exact pathogenesis of PPE still remains unclear, laser scanning microscopy was utilized to detect PLD, EP and their metabolites in and on the skin surface of patients.
RESULTS: It was shown that PLD was significantly more frequently detectable on the skin than was EP (p<0.05), whereas both substances were most frequently seen in the palms and soles. Additionally, it has been visualized that the substances reach the skin surface via sweat, where they distribute and then penetrate back into the skin.
CONCLUSION: It was concluded that a high density of sweat glands and a thick stratum corneum might represent important predestined factors for the development of PPE. These findings will help to develop efficient prevention and therapy strategies for PPE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528496

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Cutaneous Toxicity in a Laboratory Beagle (Canis lupus familiaris) after Chronic Administration of Doxorubicin Hydrochloride.

Authors:  Kathryn A Guerriero; Steven R Wilson; Nabil E Boutagy; Chi Liu; Albert J Sinusas; Caroline J Zeiss
Journal:  Comp Med       Date:  2018-02-01       Impact factor: 0.982

3.  Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature.

Authors:  Joanna Kubicka-Wołkowska; Magdalena Kędzierska; Maja Lisik-Habib; Piotr Potemski
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

4.  [Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].

Authors:  G J Burbach; T Zuberbier
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

5.  Do you know this syndrome? Hand-foot syndrome.

Authors:  Cintia Santos Braghiroli; Rodrigo Ieiri; Juliana Polizel Ocanha; Rafael Bispo Paschoalini; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

6.  Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy.

Authors:  Dandan Guo; Changying Shi; Xu Wang; Lili Wang; Shengle Zhang; Juntao Luo
Journal:  Biomaterials       Date:  2017-06-30       Impact factor: 12.479

7.  Pegylated liposomal doxorubicin in the management of ovarian cancer.

Authors:  Gabriella Ferrandina; Giacomo Corrado; Angelo Licameli; Domenica Lorusso; Gilda Fuoco; Salvatore Pisconti; Giovanni Scambia
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

Review 8.  Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects.

Authors:  Yao Zhu; Fenfen Wang; Yunchun Zhao; Xiaoling Zheng
Journal:  Eur J Hosp Pharm       Date:  2020-06-26

Review 9.  Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

Authors:  B McLellan; F Ciardiello; M E Lacouture; S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2015-06-01       Impact factor: 32.976

10.  Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin.

Authors:  Noriyuki Yokomichi; Teruaki Nagasawa; Ariella Coler-Reilly; Hiroyuki Suzuki; Yoshiki Kubota; Ryosuke Yoshioka; Akiko Tozawa; Nao Suzuki; Yoko Yamaguchi
Journal:  Hum Cell       Date:  2013-02-06       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.